APA (7th ed.) Citation

M, N., K, K., A, T., T, A., H, D., A, N., . . . T, Y. (2021). A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article. Medicine, 100(15), e25494. https://doi.org/10.1097/MD.0000000000025494

Chicago Style (17th ed.) Citation

M, Nakajo, Kitajima K, Toriihara A, Arigami T, Daisaki H, Nakamura A, Ohtsuka T, Miwa H, and Yoshiura T. "A Pilot Study on EORTC or PERCIST for the Prediction of Progression-free Survival with Nivolumab Therapy in Advanced or Metastatic Gastric Cancers: A STROBE-compliant Article." Medicine 100, no. 15 (2021): e25494. https://doi.org/10.1097/MD.0000000000025494.

MLA (9th ed.) Citation

M, Nakajo, et al. "A Pilot Study on EORTC or PERCIST for the Prediction of Progression-free Survival with Nivolumab Therapy in Advanced or Metastatic Gastric Cancers: A STROBE-compliant Article." Medicine, vol. 100, no. 15, 2021, p. e25494, https://doi.org/10.1097/MD.0000000000025494.